当前位置: 首页 > 详情页

Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease

| 导出 | |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Neurology and Neurobiology, Key Laboratory of Ministry of Education on Neurodegenerative Disorders, Xuanwu Hospital of Capital Medical University, PR China
出处:
ISSN:

关键词: Brain-derived neurotrophic factor (BDNF) Leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease (PD) Genetic association

摘要:
Parkinson's disease (PD) is a complex neurodegenerative disorder. Although the p.G2385R allele of leucinerich repeat kinase 2 (LRRK2) has been recently reported as a common genetic variant that increases the risk for typical PD exclusively among Asian population, its genetic modifiers is yet to be studied. Brain-derived neurotrophic factor (BDNF) has been shown to play an important role in the survival of dopaminergic neurons and its genetic polymorphism was associated with an increased risk for PD at an older age onset. The current case-control study was performed to investigate the interaction between LRRK2 p.G2385R and BDNF p.V66M in a Chinese PD cohort. A total of 464 PD patients and 549 controls were involved in this study. LRRK2 p.G2385R variant (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.96-5.15,p < 0.0001), not BDNF p.V66M alone significantly increased the risk of PD. However, the simultaneous presence of both LRRK2 and BDNF variants significantly enhanced the risk for PD (OR = 4.033; 95% CI = 2.188-7.435, p < 0.0001), particularly in patients with an onset age of older than 60 (OR = 6.439; 95% CI = 3.096-13.389, p < 0.0001). Our results further support that LRRK2 variants are an independent genetic risk factor for typical PD, but BDNF variants can greatly increase LRRK2-induced risk for patients with an onset age of older than 60 indicating an additive effect between the 2 genes, which might aid in studying the mechanism underlying LRRK2 parkinsonism and developing potential therapeutic strategies. (C) 2011 Elsevier Ltd. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学
JCR分区:
出版当年[2010]版:
Q2 CLINICAL NEUROLOGY
最新[2023]版:
Q2 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者机构: [1]Department of Neurology and Neurobiology, Key Laboratory of Ministry of Education on Neurodegenerative Disorders, Xuanwu Hospital of Capital Medical University, PR China
通讯作者:
通讯机构: [1]Department of Neurology and Neurobiology, Key Laboratory of Ministry of Education on Neurodegenerative Disorders, Xuanwu Hospital of Capital Medical University, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院